The chemokine MIP3α (CCL20) binds to CCR6 on immature dendritic cells. Vaccines fusing MIP3α to gp100 have been shown to be effective in therapeutically reducing melanoma tumor burden and prolonging survival in a mouse model. Other studies have provided evidence that interleukin-10 (IL-10) neutralizing antibodies (αIL-10) enhance immunologic melanoma therapies by modulating the tolerogenic tumor microenvironment. In the current study, we have utilized the B16F10 syngeneic mouse melanoma model to demonstrate for the first time that a therapy neutralizing IL-10 enhances the antitumor efficacy of a MIP3α-gp100 DNA vaccine, leading to significantly smaller tumors, slower growing tumors, and overall increases in mouse survival. The additive effects of αIL-10 were not shown to be correlated to vaccine-specific tumor-infiltrating lymphocytes (TILs), total TILs, or regulatory T cells. However, we discovered an upregulation of IFNα-4 transcripts in tumors and a correlation of increased plasmacytoid dendritic cell numbers with reduced tumor burden in αIL-10-treated mice. Interferon α receptor knockout (IFNαR1 −/− ) mice received no benefit from αIL-10 treatment, demonstrating that the additional therapeutic value of αIL-10 is primarily mediated by type I IFNs. Efficient targeting of antigen to immature dendritic cells with a chemokine-fusion vaccine provides an effective anticancer therapeutic. Combining this approach with an IL-10 neutralizing antibody therapy enhances the antitumor efficacy of the therapy in a manner dependent upon the activity of type I IFNs. This combination of a vaccine and immunomodulatory agent provides direction for future optimization of a novel cancer vaccine therapy.
Summary:
The chemokine MIP3α (CCL20) binds to CCR6 on immature dendritic cells. Vaccines fusing MIP3α to gp100 have been shown to be effective in therapeutically reducing melanoma tumor burden and prolonging survival in a mouse model. Other studies have provided evidence that interleukin-10 (IL-10) neutralizing antibodies (αIL-10) enhance immunologic melanoma therapies by modulating the tolerogenic tumor microenvironment. In the current study, we have utilized the B16F10 syngeneic mouse melanoma model to demonstrate for the first time that a therapy neutralizing IL-10 enhances the antitumor efficacy of a MIP3α-gp100 DNA vaccine, leading to significantly smaller tumors, slower growing tumors, and overall increases in mouse survival. The additive effects of αIL-10 were not shown to be correlated to vaccine-specific tumor-infiltrating lymphocytes (TILs), total TILs, or regulatory T cells. However, we discovered an upregulation of IFNα-4 transcripts in tumors and a correlation of increased plasmacytoid dendritic cell numbers with reduced tumor burden in αIL-10-treated mice. Interferon α receptor knockout (IFNαR1 −/− ) mice received no benefit from αIL-10 treatment, demonstrating that the additional therapeutic value of αIL-10 is primarily mediated by type I IFNs. Efficient targeting of antigen to immature dendritic cells with a chemokine-fusion vaccine provides an effective anticancer therapeutic. Combining this approach with an IL-10 neutralizing antibody therapy enhances the antitumor efficacy of the therapy in a manner dependent upon the activity of type I IFNs. This combination of a vaccine and immunomodulatory agent provides direction for future optimization of a novel cancer vaccine therapy.
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BACKGROUND
Our previous work has characterized the efficacy and immunogenicity of a novel therapeutic melanoma DNA vaccine platform in which amino acids 25-235 of the human version of melanoma-associated antigen gp100 are fused to a dendritic cellattracting chemokine MIP3α. 1 The human and mouse sequences of gp100 are well conserved (76% similarity), and prophylactic xenograft DNA immunizations with the human sequence have proven to be more efficacious in the B16F10 mouse model. 2 In our therapeutic model, MIP3α-gp100 enhanced immunogenicity over antigen-only vaccination and provided significant antitumor efficacy, whereas antigen-only vaccination did not. 1 Despite enhanced efficacy, the vaccine was unable to induce tumor regression. It was hypothesized that the ultimate inability of the vaccine to induce tumor regression and clearance was due to tolerogenic factors in the tumor microenvironment. 3 The microenvironment is complex with many factors influencing tolerance, such as regulatory T cells, 4 immunosuppressive cytokines, 5 T-cell checkpoint inhibitors, 4 directed evolution of tumor cells, 6 and others. 5 One generally immunosuppressive cytokine shown to play an essential role in melanoma immune tolerance is interleukin-10 (IL-10). 7 IL-10 suppresses mechanisms of immune surveillance in melanoma 8 and promotes melanoma growth by inhibition of macrophage function and induction of tumor proliferation, both directly and through enhanced angiogenesis. 7 IL-10 downregulates Major Histocompatibility Complex (MHC)/HLA type I and antigen presentation machinery in melanomas. 9, 10 Some B16 cell lines produce IL-10, 11, 12 and, in human melanomas, tumoral production of IL-10 is a poor prognostic factor. 13 Neutralizing IL-10 enhanced interferon (IFN)-γ production 14 and the efficacy of a prophylactic dendritic cell vaccine in B16 melanoma. 15 Knocking out IL-10 led to mice being more resistant to B16 tumors 14 and more sensitive to treatment with a B16-specific Fab-targeted superantigen. 16 Finally, tellurium-based compounds sensitize B16 tumors to chemotherapies by inhibiting IL-10 autocrine signaling. 11, 17 IL-10 has thus become a target for anticancer therapies targeting many different cancer types. Blocking IL-10 enhanced the delayed-type hypersensitivity response of BCG antibladder cancer vaccination. [18] [19] [20] An aptamer specifically neutralizing IL-10 provided significant protection against the CT26 colon carcinoma model. 21 Dendritic cells pulsed with tumor lysate antigens that were either IL-10-deficient or wildtype but combined with a neutralizing IL-10 antibody treatment in both cases established sufficient immune memory to protect against subsequent tumor challenge in a mouse prostate cancer model, whereas wild-type, pulsed dendritic cells did not. 22 IL-10 is a "late cytokine," and it is hypothesized that its primary physiological role is to prevent excessive immune reactivity by contributing to peripheral tolerance in settings of excessive inflammation resulting from antigen persistence. 23 The cited studies point to this IL-10 function being pivotal in maintenance of tolerance in cancer systems, including melanoma. The current study examines the role of IL-10 in our therapeutic vaccine model system.
METHODS

Animals and Tumor Model
In total, 5-6-week-old female C57BL/6 (H-2b) mice were purchased from Charles River Laboratories (Wilmington, MA) and maintained in a pathogen-free microisolation facility in accordance with the National Institutes of Health guidelines for the humane use of laboratory animals. Interferon-α receptor 1 knockout mice (IFNαr1 −/− ) carry the B6.129S2-IFNαr1 tm1Agt /Mmjax genotype maintained by Jackson Laboratories (Bar Harbor, ME). All experimental procedures involving mice were approved by the IACUC of the Johns Hopkins University (protocol numbers MO13H219, MO16H85, and MO16H147). B16F10 mouse melanoma cells were a generous gift from Dr Arya Biragyn (NIH, Baltimore, MD). In total, 6-8-week-old wild-type and 6-12-week-old knockout mice were challenged in the left flank subcutaneously with a lethal dose (5×10 4 cells) of B16F10 melanoma. Tumor size was recorded as square mm, representing tumor length×width (opposing axes) measured by calipers every 1-3 days. Mice were kept in the study until one of the following occurred: mouse death, tumor diameter eclipsing 20 mm, or extensive tumor necrosis resulting in excessive bleeding.
Plasmids, Vaccination, and αIL-10 Therapy
Vaccine consisted of purified plasmid DNA in endotoxin-free phosphate buffered saline (PBS). The plasmid encoded the MIP3α-hgp100 fusion sequence, where the antigen includes amino acids 25-235 of human gp100, as described. 1, 24 Vaccination plasmid was extracted from Escherichia coli using Qiagen (Germantown, MD) EndoFree Plasmid Maxi, Mega, and Giga Kits. Vaccine DNA purity, quality, and quantity were verified by gel electrophoresis, restriction enzyme analysis, nanodrop spectrophotometry, and insert sequencing (JHMI Synthesis and Sequencing Facility, Baltimore, MD). Mock vaccinations were comprised of endotoxin-free PBS only. DNA injections were administered into the hind leg tibialis muscle. Immediately following injection, the muscle was pulsed using an ECM 830 Electro Square Porator with 2-Needle Array Electrode (BTX Harvard Apparatus; Holliston, MA) under the following parameters: 106 V; 20 ms pulse length; 200 ms pulse interval; 8 total pulses. Vaccinations of 50 µg/dose were delivered at days noted in figure legends. As described by others, vaccination for the therapeutic model began on day 3. 1, 25, 26 Antibody against mouse IL-10 (Clone JES5.2A5; BioXcell, West Lebanon, NH) was administered intratumorally at 150 μg per dose. A typical time course of therapy begins on day 5 posttumor induction and is given every 3 days for a maximum of 6 doses. 
Intracellular Cytokine Staining and Flow Cytometry
The following protocol was utilized for intracellular cytokine staining. Enriched splenocytes or TILs were seeded onto Falcon Multiwell 24-well tissue culture-treated plates (Corning Inc.; Corning, NY) at 1×10 6 cells per well (or all cells if total is less) and stimulated for 3-4 hours at 37°C with the known immunodominant gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] (KVPRNQDWL) peptide or control HA (YPYDVPDYA) peptide (JHU School of Medicine Synthesis & Sequencing Facility; Baltimore, MD) combined with Protein Transport Inhibitor Cocktail and costimulatory anti-CD28 and anti-CD49d agonizing antibodies (eBioscience Inc., San Diego, CA). Cells were collected, washed, fixed, permeabilized, and stained using standard laboratory protocols for intracellular staining. Fixation and permeabilization buffers from Mouse Regulatory T Cell Staining Kit #2 (eBioscience Inc., San Diego, CA) were used. For pDC analysis, single-cell suspensions were stained and fixed using standard laboratory protocols for flow cytometry. Stains utilized were the following anti-mouse mAbs: PercPCy5.5 conjugated anti-CD3, PE-Cy7-mPDCA1, PE-B220, APC-IFNγ, FITC-CD8, PE-CD4, FITC-PD-1, APC-Foxp3, PE-Granzyme, AF700-Foxp3 (eBioscience Inc., San Diego, CA), Pacific Blue-CD8, PercPCy5. 
RNA Extraction and Reverse TranscriptionPolymerase Chain Reaction (RT-PCR)
Samples were taken 1 day after the dose of αIL-10 where > 80% of mice have harvestable tumors (size > 30 mm 2 ). Mice were sacrificed and portions of tumor weighing <150 mg were harvested. Tumor was minced as finely as possible and added to Trizol (Ambion by Life Technologies, Carlsbad, CA) at 1 mL Trizol per 50 mg tumor. RNA was extracted utilizing the manufacturer's protocol and including a 75% ethanol wash step. The pellet was air dried and resuspended in nuclease-free water. The cDNA reverse transcription reaction was performed with 1 μg extracted RNA and the high capacity cDNA reverse transcription kit with random primers (Applied Biosystems by Thermo Fisher, Halethorpe, MD) utilizing the manufacturer's protocol. Real-time quantitative reverse transcription-PCR (qRT-PCR) performed utilizing TaqMan Gene Expression Master Mix and TaqMan Gene Expression Assays (Applied Biosystems by Thermo Fisher, Halethorpe, MD) with probes specific for GAPDH (expression control ), IFNα4, IFNα2/11, H2-ab1, and H2-k1. qRT-PCR was run and analyzed with StepOnePlus machine and software (Applied Biosystems by Thermo Fisher, Halethorpe, MD).
Statistical Analyses
Tumor size, immunologic, RT-PCR, and flow cytometric analyses were statistically tested by 1-way ANOVA with the Tukey multiple comparisons test if multiple groups or by the Student t test if 2 groups. Mouse survival studies were statistically tested by the log-rank test. Tumor time course regressions were analyzed within the window of 8 or 10-17 days postchallenge, where treatment groups had tumors growing linearly, and were tested by mixed effect linear regression models. Correlation of pDCs and tumor size was tested by linear regression. STATA version 11.2 (StataCorp., College Station, TX) and Prism 7 (GraphPad Software Inc., San Diego, CA) were utilized for statistical analyses and figure creation. A significance level of α ≤ 0.05 was set for all experiments.
RESULTS
Effect of αIL-10 on Therapeutic Vaccination Model
Intratumoral administration of neutralizing αIL-10 antibodies was given alone and in conjunction with a chemokine-fusion DNA vaccine (MIP3α-gp100) with known antitumor efficacy in the mouse B16F10 melanoma model. 1 Figure 1A shows that αIL-10 as a monotherapy provides significant antitumor efficacy with a 43% reduction in average tumor size at day 14 postchallenge (P < 0.001). However, the tumor burden benefit of the monotherapy disappears at day 17 (Fig. 1B) , and this late, accelerated growth results in loss of a significant effect on the tumor growth rate as measured between days 10 and 17 postchallenge (Fig. 1C) . The monotherapy did provide enough efficacy to have significantly enhanced survival ( Fig. 1D ; P < 0.01), with an increase in median survival time of 11%. These data support the hypothesis that neutralization of IL-10 provides a benefit in the mouse melanoma system.
Figures 1A-D confirm results from our previous study that vaccination with MIP3α-gp100 provides consistent clinical benefit in the B16F10 mouse model, as measured by tumor size, tumor growth rate, and mouse survival. 1 When combining the vaccine regimen with αIL-10 therapy, clinical benefit at early timepoints was equivalent to both monotherapies, as seen in Figure 1A . Over time, the combination therapy continued to provide antitumor efficacy, whereas the 2 monotherapies began to lose efficacy. As seen in Figure 1B , by day 17, tumors of the combination therapy group were on average 46% smaller than αIL-10 monotherapy (P < 0.001) and 30% smaller than vaccination (P < 0.05).
Further, Figure 1C shows that the combination therapy group contains tumors that grow significantly more slowly, with a 31% reduction in growth rate compared with vaccine alone (P < 0.01) and a 51% reduction compared with αIL-10 monotherapy (P < 0.001). Finally, combination therapy provides significant enhancement in mouse survival compared with vaccine (P < 0.05) and antibody (P < 0.001) monotherapies (Fig. 1D) , with median survival enhancements of 10% and 21%, respectively.
Analysis of Infiltrating Lymphocytes
The potential mechanism for the enhanced efficacy of αIL-10 therapy seen in Figure 1 was initially hypothesized to be that IL-10 was inhibiting influx of effector T cells from blood vessels into the tumor microenvironment, as described by others. 27, 28 In this model, anti-IL-10 therapy should increase the infiltration of lymphocytes. However, while both vaccination alone and vaccination combined with αIL-10 dramatically increased the number of infiltrating lymphocytes compared with the negative control (P < 0.001), the 2 regimens were indistinguishable by this parameter (Fig. 2A) . Similarly, the number ( Fig. 2A) and percentage (Fig. 2B ) of CD8 + infiltrating cells that produced IFN-γ upon ex vivo stimulation with gp100 25-33 peptide did not differ significantly between these 2 treatment groups.
The second hypothesis for the enhanced efficacy observed with addition of αIL-10 was that IL-10 was negatively affecting T-cell effector function by inhibiting granzyme expression or by enhancing regulatory T-cell numbers in the environment, as seen in a similar model system. 15 Administration of vaccine alone or combined with αIL-10 did not significantly alter the number of CD4 + Granzyme + or CD8 + Granzyme + cells infiltrating the tumor (Fig. 2A) . Similarly, the difference in percentage of CD4 + and CD8 + infiltrating T cells with surface expression of the activation/ exhaustion marker programmed death ligand-1 (PD-1) was not significant between the vaccine alone and vaccine plus αIL-10 groups (Fig. 2B) . Also, in contrast to Kalli et al, 15 no difference was seen in the percentage of infiltrating CD4 + T cells that had a regulatory phenotype (Fig. 2B) . The ratio between infiltrating CD8 + T cells and regulatory CD4 + cells, a parameter generally correlating with T-cell-based antitumor efficacy, 29, 30 was also not significantly different between groups receiving vaccine alone and groups receiving both vaccine and αIL-10 (Fig. 2C ).
Expression and Cellular Source of IL-10 Responsive Genes
As αIL-10 did not appear to be affecting T cells directly, intratumoral expression levels were assessed for some of the genes that are both known to be regulated by IL-10 and capable of indirectly enhancing infiltrating T-cell responses. Genes such as H2-K1 (MHC-I), 10,31,32 H2-ab1 (MHC-II), 33 and Ifnα 34,35 are known to be negatively regulated by IL-10 under certain conditions. The transcriptional levels of these candidate genes in tumor lysates were analyzed by qRT-PCR 1 day after administration of αIL-10. Relative fold-expression values were calculated as noted in the Methods section and figure caption. Expression levels of H2-k1, H2-ab1, and Ifnα2/11 remained relatively unchanged in vaccine alone versus vaccine plus αIL-10 (Fig. 3A) . Expression levels of Ifnα4 were upregulated 2.8-fold (P < 0.05) when adding αIL-10 to the vaccine (Fig. 3A) . In addition, Ifnα4 in the vaccine-only group was upregulated 6.7-fold compared with negative control, so the combination group was upregulated 18.7-fold compared with the negative control.
It is known in the literature that pDCs are primary producers of type I IFNs. 36 Therefore, the presence of pDCs infiltrating the tumors were analyzed 2 days after the third αIL-10 treatment. For these data, the system was simplified to treatments of αIL-10 only, without vaccinations. Intratumoral pDCs were increased by 55.0% (P < 0.05) at this timepoint when mice were given αIL-10 (Fig. 3B) . Further, the concentration of pDCs had a significant correlation with reduced tumor size ( Fig. 3C ; r 2 = 0.636; P < 0.05).
IFNαr1 −/− Knockout Mice
The previous experiments indicate that IFNα4 expression correlates with the antitumor efficacy of αIL10 treatment and that the cell type known for producing type I IFNs has elevated levels in tumors of αIL-10-treated mice; however, the results do not differentiate between IFNα4 expression and pDCs being associated with and directly causing the enhanced antitumor efficacy. To address this issue, the standard therapeutic protocol was assessed utilizing mice with IFNα-receptor 1 knocked out (IFNαr1
−/−
). Mice deficient in the receptor are unable to react to the IFNα family of cytokines. 37 In Figure 4A , tumor sizes at day 17 post challenge of wild-type vaccine, αIL-10-treated mice were on average 41.1% smaller compared with wild-type vaccine-only (P < 0.05), consistent with previous results. Wild-type mice receiving vaccine only bore tumors that were not significantly different in size compared with IFNαr1 −/− mice that were vaccinated alone or were additionally given αIL-10. Importantly, the tumor sizes of the combination treatment in wild-type mice were 51.1% smaller than those of IFNαr1 −/− mice given the combination treatment ( Fig. 4A ; P < 0.001).
Tumor growth rates followed a similar course (Fig. 4B ). Wild-type combination treatment mice had significantly lower tumor growth rates than wild-type vaccine-only (36.8% less, P < 0.05), IFNαr1 −/− vaccine-only (38.0% less, P < 0.01), and IFNαr1 −/− combination treatment groups Boxplot whiskers delineate the range, and the box represents the middle 50% with median line. C, Tumor growth rate was assessed between days 10 and 17, at which point tumor growth of the negative control group approached when mice began to be censored due to attainment of tumor size endpoints. Graph shows data points with SEs and linear regression lines. Numerical slopes are indicated adjacent to their respective regression lines. The data are representative of 4-9 experiments with 5-9 mice per experiment for sample sizes ranging from 28 to 53 per group. The group combining vaccination with αIL-10 therapy shows significantly slower tumor growth than all other treatments as evaluated by a statistical mixed effects regression model. D, Effect of αIL-10 on mouse survival. Mice were removed from the study at the following endpoints: death, tumor diameter surpassing 2 cm, or excessive tumor bleeding and ulceration. Data are representative of 3-4 experiments comprising a total of 22-29 mice per group and were evaluated by log-rank test. IL indicates interleukin. *P < 0.05; **P < 0.01; ***P < 0.001.
(51.5% less, P < 0.001). Similarly, survival analysis (Fig. 4C ) demonstrated that wild-type mice receiving both treatments survived significantly longer than wild-type vaccine-only mice (P < 0.01), IFNar1 −/− vaccine-only mice (P < 0.001), and IFNar1 −/− mice receiving both treatments (P < 0.001). The group of wild-type mice with both treatments showed an increase in median survival of 19.0% compared with the wild-type vaccine-only group, 13.6% compared with the IFNar1 −/− vaccine-only group, and 25.0% compared with the IFNar1 −/− group with both treatments. The wild-type vaccine-only group showed no significant difference in growth or survival compared with the IFNar1 −/− group receiving either vaccine alone or vaccine plus αIL-10.
DISCUSSION
In this study, neutralizing IL-10 at the tumor site enhances the antitumor efficacy of a DNA MIP3α-gp100 therapeutic vaccine. The αIL10 therapy does not appear to directly alter T-cell tumor infiltration, T-cell differentiation, or vaccine immunogenicity, as measured by vaccine peptidereactive tumor-infiltrating CD8 + T cells. Blockade of IL-10 has been shown to enhance T-cell responses to an otherwise ineffective DNA vaccine in a lymphocytic choriomeningitis virus model. 38 IL-10 neutralization also enhanced a dendritic cell-based antimelanoma prophylactic vaccine and the αIL-10 monotherapy correlated with enhanced CD4 + granzyme + TILs and reduction of regulatory CD4 + Foxp3 + TILs. 15 However, in the present model, levels of CD8 + TILs that produced IFN-γ upon vaccine peptide stimulation did not significantly change when adding αIL-10 treatments to vaccinated mice, nor did levels of CD4 + granzyme + TILs or regulatory CD4 + Foxp3 + TILs. It is possible that this difference is due to analysis of the monotherapy 15 versus the combination with vaccine as analyzed here. Overall levels of TILs did not change significantly either, suggesting that αIL-10 was not altering T-cell migration or endothelial cell permeability.
Instead, the mechanism by which αIL10 therapy enhances antitumor efficacy is associated with intratumoral expression of IFNα4. IFNα4 and IFNα11 are highly active in mice, 39 and so levels of both were analyzed. Although Ifnα2/11 saw no increase in expression, Ifnα4 expression was C, The ratio of CD8 + TILs to regulatory CD4 + TILs. All data are from 2 to 3 independent experiments of 3-8 mice each. Groups were evaluated by ANOVA with the Tukey multiple comparisons test. Error bars represent the SE. IL indicates interleukin; TIL, tumor-infiltrating lymphocyte. *P < 0.05; **P < 0.01; ***P < 0.001.
increased almost 3-fold in combination treatment compared with vaccine-only and ∼18-fold compared with the negative control. In addition, the cell type that primarily produces type I IFNs, pDCs, 36 was shown to be enhanced in the tumor environment. Levels of pDCs significantly correlated with reduced tumor growth across treatment and control groups, indicating that this parameter may be important for B16F10 tumor control. This correlation was then shown to be the primary driver responsible for the efficacy of αIL-10 treatment. Knocking out a chain of the common receptor for interferon α cytokines (Ifnαr1 −/− ) caused loss of the enhanced vaccine efficacy phenotype associated with αIL-10 therapy. Ifnαr1 −/− mice receiving vaccination and αIL-10 treatment did not show significant differences compared with wild-type or Ifnαr1
−/− mice that were given vaccine-only, but did have larger tumors, a faster tumor growth rate, and reduced survival compared with wild-type mice given both vaccine and αIL-10. Clearly, αIL-10 efficacy in combination with a MIP3α-gp100 vaccine is primarily mediated by type I IFNs and the responses they induce. Unexpectedly, the course of B16F10 progression remained the same between wild-type and Ifnαr1 −/− mice that received vaccine-only, indicating that baseline vaccine efficacy is independent of type I IFNs.
Identification of the role of type I IFNs in the observed anti-IL-10 effects facilitates development of a model that explains the patterns of tumor growth observed in the different treatment groups. An increase in type I IFNs could provide a more general benefit by enhancing expression of antiangiogenic factors, 40 macrophage cytotoxicity, 42 lymphocyte cytotoxicity, 43 and/ or dendritic cell activity. 44, 45 It is possible that the slight reduction in tumor size due to the direct antitumor effects of type I IFNs at early timepoints in the combined treatments group allowed the vaccine response to achieve better efficacy over time due to the reduced tumor burden. However, this hypothesis is unlikely in the vaccine and αIL-10 combination group, considering that it is not until day 17 postchallenge that the combination group significantly separates from the monotherapies. If the enhanced efficacy of the combination group were due to direct antitumor effects, one would expect to see earlier separation.
The tumor growth patterns in the IL-10-treated groups of mice suggest 2 distinct effects, both of which have been previously associated with the antitumor efficacy of type I IFNs. The early suppression of tumor growth observed in the mice treated with anti-IL-10 alone could be readily attributable to the direct antitumor effects of type I IFNs, as indicated. However, this effect is attenuated over time and by day 15 the slope of the tumor growth rate in the anti-IL-10-treated mice sharply increases. A recent report suggests that loss of type I IFN activity against melanoma cells can be reversed with treatment with 5-aza-2′-deoxycitidine, suggesting that the loss of direct cell-killing activity is attributable to DNA methylation events affecting IFN-stimulated genes. 46 However, the well-described effects of IFN's on enhanced DC function and T-cell priming 44, 45 would likely have occurred before the attenuation of type I IFN function but would not be manifest until the vaccine-induced immune response becomes functional at the later stages of tumor growth. This delayed expression of the early type I IFN effects on the inductive stage of the immune response likely account for the enhanced extended efficacy observed in the combined treatment group compared with treatment with either vaccine or anti-IL-10 alone.
Although it is acknowledged that the current enhancements in efficacy are modest, new therapy alternatives are essential for the growth of the field. This study shows that this flexible and novel dendritic cell-targeting vaccine platform can be enhanced by immunomodulating agents. Future studies will focus on other immunodulators currently in the clinic, alone, or combined with αIL-10, such as αPD-1, αPDL-1, αCTLA-4, αLAG-3, and/or others. 47 As the effect of αIL-10 is mediated by type I IFNs, we also −/− mice on vaccination and αIL-10 treatment. Mice were removed from the study at the following endpoints: death, tumor size surpassing 2 cm in any dimension, or excessive tumor bleeding and ulceration. Groups were evaluated by log-rank test. Data represent 2-3 experiments of 4-6 mice per group per experiment. IFN indicates interferon; IL, interleukin; WT, wild-type. *P < 0.05; **P < 0.01; ***P < 0.001. plan on directly administering IFNα to determine whether vaccine efficacy can be enhanced further by this pathway. Notably, this mechanism has clinical relevance. IFN-α2b treatment has shown benefit in patients with early stage II/ III melanomas, 48 and clinical studies have elucidated that adjuvant IFNα therapy significantly increased disease-free survival and sometimes overall survival. 49 IFNα adjuvant therapy became the first immunotherapeutic agent to show significant benefits in survival in a phase III randomized controlled trial and is a part of the current standard of care for patients with advanced stage II or stage III melanoma. 49, 50 This model identifies paths by which further enhancement of tumor growth inhibition might be achieved and provides direction for future studies.
IL-10 is a complex cytokine with pleiotropic effects. However, the results of this study conclusively show that intratumoral neutralization of IL-10 provides therapeutic efficacy against B16 melanoma alone, and that the efficacy is further enhanced when used in combination with a DNA vaccine. This study demonstrates that Ifnα4 expression is upregulated in the tumor and that pDCs are present at higher levels in the tumor after αIL-10 doses. Finally, action of type I IFNs is necessary for αIL-10 treatment efficacy. Further study could guide investigators into understanding the specific contexts that provide the best antitumor efficacy from IL-10 neutralization.
